Intellective Bio Congratulates Its Partner Innogen on Successful HKEX Main Board Listing-Newsroom

Intellective Biologics ("Intellective Bio"), a leading global CDMO, warmly congratulates its partner Guangzhou Innogen Pharmaceutical Group Co., Ltd. ("Innogen", Stock Code: 02591) on its official listing on the Main Board of the Stock Exchange of Hong Kong Ltd. on 15 August 2025.

Innogen is a science-driven biopharmaceutical company committed to providing innovative, accessible and affordable high-quality medicines for patients with metabolic diseases. Its core product, Yinuoqin^® (Esupaglutide α Injection), China's first domestically developed fully human ultra-long-acting GLP-1 drug, received approval from the National Medical Products Administration (NMPA) on 26 January 2025, for the treatment of adults with Type 2 Diabetes.

Alex Li, CEO of Intellective Bio, stated:

"Congratulations to Innogen on its successful listing on the Main Board of the Stock Exchange of Hong Kong Ltd.! As a partner of Innogen, we are truly honoured to have supported its innovative drug project in the metabolic field and to witness this landmark moment. Moving forward, Intellective Bio will continue to collaborate closely with Innogen and more partners to efficiently advance the delivery of innovative therapies to patients worldwide."

As the CDMO partner for Yinuoqin® from clinical development through commercialisation, Intellective Bio played a pivotal role in its R&D and scale‑up manufacturing by leveraging its comprehensive end-to-end commercial capabilities and robust technology platforms. Yinuoqin® is one of the commercial projects successfully approved with Intellective Bio's support. Its global launch ceremony was grandly held at Intellective Bio's Changshu site on 18 February 2025.

Intellective Bio's commercial progression is accelerating rapidly. The company currently has two commercial projects successfully approved, has passed three Pre-Approval Inspection (PAI) audits, provides ongoing support to 13 late-stage clinical projects, and anticipates achieving commercial approval for 11 projects by 2027. 

About Innogen

Innogen is the first company in Asia and the third globally to advance an original human long-acting GLP-1 receptor agonist into the drug registration and approval stage. Its core product, Efsubaglutide α (brand name: Yinuoqing®), has entered the commercial phase. As a science-driven and innovation-oriented biopharmaceutical company, Innogen is at the forefront of developing novel therapies for diabetes and other metabolic diseases. With fully integrated, end-to-end capabilities in research, manufacturing and commercialisation, we are committed to becoming a global leader in the field of metabolic disease therapeutics.

Dr. Qinghua Wang, Innogen’s founder, Chairman, and CEO, is also the inventor of Efsubaglutide α. He is a nationally recognised expert and served as Chief Scientist for China’s “Major New Drug Innovation” programme under the 13th Five-Year National Science and Technology Plan.

Yinuoqing® (Efsubaglutide α Injection) is a prescription medicine and should be obtained through legitimate channels with a prescription from a licensed physician or other qualified healthcare professional. It must be used safely and appropriately under the guidance of physicians, pharmacists, or other certified medical personnel.